Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors

Clinical Cancer Research

Volumn 12, Issue 18, 2006, Pages 5587-5595

  Moosmayer, Dieter ^a   Berndorff, Dietmar ^a   Chang, Chien Hsing ^b   Sharkey, Robert M ^e   Rother, Axel ^d   Borkowski, Sandra ^a   Rossi, Edmund A ^b   McBride, William J ^c   Cardillo, Thomas M ^c   Goldenberg, David M ^e   Dinkelborg, Ludger M ^a  

^a BAYER PHARMA AG   (Germany)

^b IBC Pharmaceuticals Inc   (United States)

^c IMMUNOMEDICS INC   (United States)

^d INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^e CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; FIBRONECTIN; IMMUNOPROTEIN L19; INDIUM 111; IODINE 125; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AP39XM679; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG DISTRIBUTION; FEMALE; GLIOBLASTOMA; HAPTEN CARRIER COMPLEX; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RADIOIMMUNOTHERAPY; SOLID TUMOR; XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; DRUG DELIVERY SYSTEMS; FEMALE; GLIOBLASTOMA; HUMANS; IODINE RADIOISOTOPES; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33749325410     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0210     Document Type: Article

References (36)

1. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46 Suppl 1:115-27s.
2. Sharkey RM, Blumenthal RD, Hansen HJ, Goldenberg DM. Biological considerations for radioimmunotherapy. Cancer Res 1990;50:964-9s.
3. Behr TM, Becker WS, Sharkey RM, et al. Reduction of renal uptake of monoclonal Ab fragments by amino acid infusion. J Nucl Med 1996;37:829-33.
4. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther 2002;1:553-63.
5. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 2003;44:400-11.
6. Sharkey RM, Karacay H, Cardillo TM, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 2005;11:7109-21.
7. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal Ab conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989;30:1358-66.
8. 131I- labeled bivalent hapten. J Nucl Med 2000;41:480-7.
9. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 2000;97:1802-7.
10. 90Y-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N′, N′-tetraacetic acid (DOTA)-biotin. Cancer Res 2002;62:5755-60.
11. Subbiah K, Hamlin DK, Pagel JM, et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med 2003;44:437-45.
12. Sharkey RM, Karacay H, Chang CH, et al. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 2005;19:1064-9.
13. Karacay H, Brard P-Y, Sharkey RM, et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 2005;11:7879-85.
14. Kraeber-Bodere F, Sai-Maurel C, Campion L, et al. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenografts. Mol Cancer Ther 2002;1:267-74.
15. Castellani P, Viale G, Dorcaratto A, et al. The fibronectin containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994;59:612-8.
16. Fini A, Viti F, Santucci A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998;273:21769-76.
17. Tarli L, Balza E, Viti F, et al. A high-affinity human antibody fragment that targets tumoral blood vessels. Blood 1999;94:192-8.
18. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61:711-6.
19. Carnemolla B, Borsi L, Balza E, et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002;99:1659-65.
20. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-9.
21. Berndorff D, Borkowski S, Sieger S, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 2005;11:7053-63.
22. Cunha AE, Clemente JJ, Gomes R, et al. Methanol induction optimization for scFv antibody fragment production in Pichia pastoris. Biotechnol Bioeng 2004;86:458-67.
23. Borsi L, Balza E, Bestagno M, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002;102:75-85.
24. Scheuermann J, Viti F, Neri D. Unexpected observation of concentration-dependent dissociation rates for antibody-antigen complexes and other macromolecular complexes in competition experiments. J Immunol Methods 2003;276:129-34.
25. Rossi EA, Chang C-H, Losman MJ, et al. Pretargeting of CEA-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res 2005;11:7122-9.
26. Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide 1,3,4,6-tetrachloro-3α-6α- diphenylglycouril. Biochem Biophys Res Commun 1978;80:849-57.
27. Birchler M, Neri G, Tarli L, Halin C, Viti F, Neri D. Infrared photodetection for the in vivo localization of phage-derived antibodies directed against angiogenic markers. J Immunol Methods 1999;231:239-48.
28. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003;63:354-63.
29. Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations. New York: Society of Nuclear Medicine; 1988.
30. Pizarello DJ, Witcofski RL. Medical radiation biology. Philadelphia: Lea & Febiger; 1982.
31. Sharkey RM, Karacay H, Richel H, et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res 2003;9:3897-9135.
32. Carnemolla B, Balza E, Siri A, et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989;108:1139-48.
33. Vangeepuram N, Ong GL, Mattes MJ. Processing of antibodies bound to B-cell lymphomas and lymphoblastoid cell lines. Cancer 1997;80:2425-30.
34. Sharkey RM, Cardillo TM, Rossi EA, et al. Signal amplification in molecular imaging by pretargeting a multivalent bispecific antibody. Nature Medicine 2005;11:1250-5.
35. Bureau of Radiological Health. Radiological health handbook. Revised ed. Jan. 1970. Rockville (MD): U.S. Department of Health, Education, and Welfare.
36. 131I-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res 2001;7:3186-92.